Estimated additional payments upon achievement of development and commercial milestones
Biogen·Products & Services·2 segments
Breakdown
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|
| Felzartamab | — | — | — | — | — | $730.00M |
| Felzartamab And Izastobart/HIB210 | $640.00M | $640.00M | $640.00M | $640.00M | $640.00M | — |
| Total | $640.00M | $640.00M | $640.00M | $640.00M | $640.00M | — |
Segments
Felzartamab And Izastobart/HIB210View metric
FelzartamabView metric